Analyzing...
Loading company...
Anthem Biosciences Ltd operates in pharmaceutical and biotechnology research, manufacturing, and development. The company delivers innovative healthcare solutions and high-quality products, supporting medical research and patient care across various therapeutic areas.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,089 Cr revenue.
COGS 38.1%, employees 12.6%.
“mid teens around 15 to 16%”
“guidance of 20% plus on EBITDA”
“EBITDA was stronger than ever at INR $6.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 21.1%▲ | 10.3% |
| ROCE | 28.0%▲ | 13.7% |
| Net Margin | 29.5%▲ | 7.6% |
| EBITDA Margin | 44.4%▲ | 15.4% |
| Debt To Equity | 0.01x▼ | 0.15x |
Historical valuation data not available.
| (₹ Cr) | TTM |
|---|---|
| Revenue | ₹2,089 Cr |
| Other Income | ₹182 Cr |
| Total Income | ₹2,271 Cr |
| COGS | ₹795 Cr |
| ₹1,344 Cr | |
| Profit Before Tax | ₹903 Cr |
| Exceptional Items | (₹24 Cr) |
| ₹233 Cr | |
| Net Profit | ₹671 Cr |
| Other Comprehensive Income | (₹2 Cr) |
| EPS | ₹11.94 |
| Diluted Shares | ₹56 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Anthem Biosciences Limited has informed the Exchange about Transcript
Anthem Biosciences Limited has submitted the Exchange the voting results and a copy Srutinizers report of the 20th Annual General Meeting held on July 22, 2026.
Anthem Biosciences Limited has informed the Exchange about Link of Recording
Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Anthem Biosciences Limited has informed the Exchange regarding a revised press release dated July 21, 2026, titled "Press Release on Unaudited Financial Results for the Quarter ended June 30, 2026".
Anthem Biosciences Limited has informed the Exchange about Investor Presentation
Anthem Biosciences Limited has informed the Exchange regarding a press release dated July 21, 2026, titled "Press Release on the Unaudited Financial Results for the quarter ended June 30, 2026".
Anthem Biosciences Limited has informed the Exchange about Investor Presentation
Anthem Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Anthem Biosciences Limited has informed the Exchange about Schedule of meet
Anthem Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Anthem Biosciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Reg...
Anthem Biosciences Limited has informed the Exchange regarding the Letter to Shareholders providing the weblink and navigation path for accessing the Annual Report for the FY 2025-26 pursuant to Regul...
Anthem Biosciences Limited has informed the Exchange about Newspaper Publication regarding pre-dispatch intimation of Notice of 20th Annual General Meeting of the Company
The Exchange has sought clarification from Anthem Biosciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regu...